Keith Katkin - 04 Feb 2026 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, as Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
04 Feb 2026
Net transactions value
$0
Form type
4
Filing time
06 Feb 2026, 16:13:08 UTC
Previous filing
16 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Katkin Keith Director C/O SYNDAX PHARMACEUTICALS, INC., 730 THIRD AVENUE, FLOOR 9, NEW YORK /s/ Michael A. Metzger, as Attorney-in-Fact 06 Feb 2026 0001314596

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Award $0 +24,000 +24% $0.000000 124,000 04 Feb 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.